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Abstract
 
An increasing number of studies have documented the central role of T cell costimulation in
autoimmunity. Here we show that the autoimmune diabetes-prone nonobese diabetic
(NOD) mouse strain, deficient in B7-2 costimulation, is protected from diabetes but develops
a spontaneous autoimmune peripheral polyneuropathy. All the female and one third of the
male mice exhibited limb paralysis with histologic and electrophysiologic evidence of severe
demyelination in the peripheral nerves beginning at 20 wk of age. No central nervous system
 
lesions were apparent. The peripheral nerve tissue was infiltrated with dendritic cells, CD4
 
 
 
,
and CD8
 
 
 
 T cells. Finally, CD4
 
 
 
 T cells isolated from affected animals induced the disease in
NOD.SCID mice. Thus, the B7-2–deficient NOD mouse constitutes the first model of a
spontaneous autoimmune disease of the peripheral nervous system, which has many similari-
ties to the human disease, chronic inflammatory demyelinating polyneuropathy (CIDP). This
model demonstrates that NOD mice have “cryptic” autoimmune defects that can polarize to-
ward the nervous tissue after the selective disruption of CD28/B7-2 costimulatory pathway.
Key words: autoimmunity • peripheral neuropathy • B7-2 costimulation • animal model • 
NOD mice
 
Introduction
 
Engagement of the T cell receptor alone is insufficient to
cause conventional activation of T cells and differentiation
into effector cells. Rather, costimulatory signals are re-
quired generally to promote the expansion of antigen-reac-
tive populations of T cells, migration of cells to sites of in-
flammation, and the production of soluble mediators of
inflammation (1–4). One of the prominent costimulatory
molecules, CD28, interacts with B7-1 (CD80) and B7-2
(CD86) on antigen-presenting cells (4). Drugs that block
this critical costimulatory pathway have been shown to in-
hibit both the development and progression of many au-
toimmune diseases (5–10). Cytotoxic T lymphocyte anti-
gen (CTLA)4-Ig, a soluble antagonist of the CD28/B7
pathway, completely inhibits the development of experi-
mental autoimmune encephalitis and the onset of collagen-
induced arthritis as well as other autoimmune diseases (8–
10). B7-1 and B7-2 molecules have been shown to play
distinct roles in several murine models of autoimmune dis-
eases, including type I diabetes and experimental autoim-
mune encephalitis (6, 7). We have previously reported that
blockade of B7-1 in the spontaneous autoimmune NOD
mouse strain induced diabetes with faster and higher inci-
dence than untreated NOD animals (7). In contrast, in this
study we show that blockade of B7-2 prevented diabetes;
however, autoimmunity is redirected from the pancreas to
the peripheral nerves, leading to the development of a
CD4
 
 
 
 T cell–mediated spontaneous autoimmune periph-
eral neuropathy in these mice.
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Materials and Methods
 
Mice.
 
B7-2 knockout (KO)
 
*
 
 mice (11) were backcrossed to
NOD mice for nine generations and then intercrossed to gener-
ate KO mice. The genotypes were determined by PCR using
B7-2–specific primers (sense: TAT-TTC-AAT-GGG-ACT-
GCA-TAT-C, antisense: CGA-TCA-CTG-ACA-GTT-CTG-
TTA). NOD mice were purchased from Taconic and then bred
in the animal care facilities at The University of Chicago or
UCSF. Experiments were complied with the standards set out in
the guidelines of The University of Chicago and UCSF.
 
Histology and Immunohistochemistry.
 
Hematoxylin and eosin
staining was performed on 5-
 
 
 
m sections of formalin-fixed tissues.
Toluidine blue stained 1-
 
 
 
m sections were prepared from forma-
lin fixed, glutaraldehyde postfixed nerve segments after plastic em-
bedding. Immunohistochemistry was performed using the avidin-
biotin method (12). Tissues were snap frozen in OCT and 5-
 
 
 
m
cryostat sections were incubated with: rat mAbs to CD3 (L363–
29B), CD4 (GK1.5), CD8 (3.155); hamster mAbs to dendritic
cells (N418); or species- and isotype-specific nonreactive control
mAbs overnight at 4
 
 
 
C. Room temperature incubation with bi-
otinylated rabbit anti–rat or goat anti–hamster secondary Ab (Vec-
tor Laboratories) for 30 min was followed by a 1-h incubation
with streptavidin-biotin complex (Vector Laboratories). Diami-
nobenzidine was used as the chromogen. Tease preparations of
peripheral nerve were performed using published methods (13).
 
Fluorescence Immunohistochemistry.
 
Slides were stained using
Tyramide Signal Amplification (TSA) Direct Kit (NEN Life Sci-
ence Products) according to the manufacturer’s instructions. Sec-
tions from each group were thawed, air-dried, fixed in acetone at
room temperature, and rehydrated in 1
 
 
 
 PBS. Nonspecific stain-
ing was blocked using anti-CD16/CD32, (Fc
 
 
 
 III/II receptor,
2.4G2; BD PharMingen), and an avidin/biotin blocking kit (Vec-
tor Laboratories) in addition to the blocking reagent provided by
the TSA kit. Slides were stained with the following biotin-conju-
gated Abs: anti-CD4 (H129.19) and anti-CD80 (16–10A1) (BD
PharMingen). Sections were counterstained with 4,6-diamidino-
2-phenylindole (DAPI; Sigma-Aldrich) and then coverslipped
with Vectashield mounting medium (Vector Laboratories). Slides
were examined by epifluorescence using a chroma triple-band fil-
ter (Chroma Technology Corporation). Four serial sections from
each sample per group were analyzed at 100
 
 
 
 and 400
 
 
 
.
 
Electrophysiological Studies.
 
Studies were performed on sciatic
nerves on mice anesthetized with Nembutal (80 mg/kg). Record-
ing needle electrodes were placed subcutaneously in the footpad.
The sciatic nerve was stimulated distally at the ankle and proxi-
mally at the sciatic notch by a 0.1-ms rectangular pulse using a pair
of monopolar needle electrodes. Recordings were obtained on a
TECA Neurostar electromyograph (TECA Corp.) with a filter set-
ting of 2 Hz to 10 kHz. The distal or proximal latencies corre-
sponding to the time laps between the distal or proximal stimula-
tions and the beginning of the first compound muscle action
potential were measured. Conduction velocities were calculated by
dividing the distance between distal and proximal stimulation sites
with the difference between the distal and proximal latencies. The
peak-to-peak amplitude of compound muscle action potentials was
measured. The comparison of this amplitude between normal and
neuropathic mice was used to determine partial conduction block.
 
Adoptive Transfer.
 
CD4
 
 
 
 T cells (positive fraction) and CD4
 
 
 
T cell–depleted cells (flow through) were separated on a VS
 
 
 
 col-
 
umn (Miltenyi Biotec) after staining with anti–CD4-biotin
(GK1.5) and streptavidin microbeads (Miltenyi Biotec). Total
cells or purified cells were stimulated with 1 
 
 
 
g/ml of anti-CD3
(145–2C11) and anti-CD28 (PV-1) for 48 h. IL-2 (20 U/ml) was
added to the culture of the CD4
 
 
 
 T cell–depleted cells. 8–15 
 
 
 
10
 
6
 
 total cells and CD4
 
 
 
 T cell–depleted cells (
 
 
 
0.3% CD4
 
 
 
 T
cells) and 4–6 
 
 
 
 10
 
6
 
 CD4
 
 
 
 T cells (
 
 
 
92% pure) were injected
intravenously into 4–8-wk-old NOD.SCID mice.
 
Flow Cytometry Analysis.
 
Spleens and sciatic nerves were cut
into small fragments and incubated in RPMI 1640 supplemented
with 1.6 mg/ml collagenase (type IV; Sigma-Aldrich) and 200
 
 
 
g/ml DNase I (Boehringer) at 37
 
 
 
C for 30 min. Cells were dis-
sociated by repeated pipetting, reincubated at 37
 
 
 
C for 10 min,
washed with PBS 3% serum, and resuspended in staining buffer
(PBS, 3% serum, 0.02% azide). Cells were double stained with
FITC-conjugated CD11b (M1/70) and PE-conjugated CD45
and biotin-conjugated CD11c (N418) mAbs followed by strepta-
vidin-allophycocyanin staining and analyzed on a FACSCali-
bur™ (Becton Dickinson).
 
Results
 
This study was designed to explore the role of costimula-
tion in the spontaneous autoimmune-prone NOD mouse
strain, a prototypic murine model of type 1 Diabetes Melli-
 
*
 
Abbreviations used in this paper: 
 
CIDP, chronic inflammatory demyelinat-
ing polyneuropathy; CNS, central nervous system; KO, knockout; SAPP,
spontaneous autoimmune peripheral polyneuropathy; WT, wild-type.
Figure 1. B7-2 blockade in NOD mice prevents diabetes but induces
a peripheral neuropathy (a and b). B7-2–deficient mice (reference 14)
were backcrossed to NOD mice for nine generations and then inter-
crossed to generate B7-2 WT (B7-2 / ) and B7-2 KO (B7-2 / ) NOD
mice. B7-2 /  (n   10) and B7-2 /  (n   10) females were checked
weekly for blood glucose levels (a) and B7-2 /  females and males were
checked weekly for clinical signs of neuropathy (hind leg weakness and
inability to grasp wire bar lid of cages) (b). Inset: neuropathic mouse dis-
playing deterioration of hind limb control and coordination. (c and d)
WT NOD females were treated with 50  g of anti–B7-2 blocking mAb
(GL-1) every other day between 2 to 4 wk of age plus at weeks 5, 6, and
7 (n   6) or with PBS (n   5). Incidence of diabetes (c) and neuropathy
(d) were evaluated at weekly intervals. 
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tus (14). In these mice, insulitis first appears between 2–4
wk of age, and diabetes is detected beginning at 15 wk of
age. Diabetes develops in 
 
 
 
70% of female mice but occurs
in only 30% of male mice. Elimination of B7-2 expression
by breeding NOD mice onto the B7-2–deficient back-
ground (11) prevented the development of hyperglycemia
in virtually 100% of both the female (Fig. 1 a) and male
(data not shown) animals. Similar results were observed af-
ter anti–B7-2 Ab therapy (4; Fig. 1 c). However, beginning
at 20 wk of age, the B7-2 KO NOD mice began to exhibit
a symmetrical mild hind leg paralysis, slowly progressing to
a generalized limb paralysis such that by 32 wk of age,
100% of female and 30% of the male B7-2 KO mice had
succumbed to the disease (Fig. 1 b). The majority of af-
fected animals exhibited full hind leg paralysis, moderate
fore leg paralysis, and could only walk with difficulty (Fig.
1 b, inset). There was no evidence of central nervous sys-
tem (CNS) disorders. The disease was never observed in
B7-2 KO mice bred to the C57BL/6 or 129/Sv nonauto-
immune mouse background (unpublished data). However,
a similar paralytic disease was noted in one third of NOD
mice treated with anti–B7-2 mAb but not in PBS-treated
mice (Fig. 1 d) or NOD mice treated with isotypic control
Abs (data not shown). These results support the important
regulatory role of B7-2 in the development of this disease
as two independent approaches, genetic modification of
B7-2 in NOD mice and anti–B7-2 mAb treatment of wild-
type (WT) NOD mice resulted in the same disease. Inter-
estingly, the subset of NOD mice that became diabetic
after the anti–B7-2 mAb therapy did not develop the pe-
ripheral neuropathy while none of the mice exhibiting the
neuropathy became diabetic. The data suggest that elimina-
tion of the CD28/B7-2 interactions polarized the auto-
immune disorder in the NOD mice from the previously
described autoimmune diabetes to a spontaneous autoim-
mune peripheral polyneuropathy (SAPP).
The neuropathic mice were examined histologically for
evidence of an inflammatory infiltrate in the endocrine and
nervous system tissues (Fig. 2). WT NOD mice exhibited
significant cellular infiltrates and tissue destruction in the
pancreas (Fig. 2 a) and salivary glands (data not shown) typ-
ically targeted in this autoimmune-prone strain of mice. In
contrast, there was no infiltrate or pathology in the nervous
system in these animals (Fig. 2, c, e, g, and i). B7-2 KO an-
imals affected with SAPP exhibited strongly reduced infil-
trates in pancreatic islets (Fig. 2 b) and salivary glands (data
Figure 2. Inflammation in the peripheral nervous system in neuropathic B7-2 /  NOD mice. Hematoxylin and eosin staining on sections of pancreas
(a and b), brain cortex (c and d), spinal cord (e and f), dorsal root ganglion (g and h), and sciatic nerve (i and j) in 25–30-wk-old B7-2 /  neuropathic fe-
males (b, d, f, h, and j) and age-matched B7-2 /  control females (a, c, e, g, and i). (a–d and f–j) Original magnification:  500. (e and f) Original magni-
fication:  250. B7-2 /  mice, but not B7-2 /  mice, exhibit severe insulitis (a) whereas B7-2 /  mice, but not B7-2 /  mice, exhibit inflammation in
dorsal root ganglions (h) and nerves (j). 
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not shown). It should be pointed out that peri-insulitis was
present in some mice consistent with a retention of at least
some autoreactive diabetic cells. However, insulitis in B7-
2KO NOD mice appeared much later than in NOD mice
and did not progress from peri-insulitis to severe insulitis.
In sharp contrast, neuropathic B7-2KO NOD mice dis-
played severe inflammation of the peripheral nervous sys-
tem. The dorsal and ventral spinal roots, the dorsal root
ganglia, and peripheral nerves had mononuclear infiltrate
(Fig. 2, h and j, and data not shown). The skeletal muscles
showed focal neurogenic atrophy in severely affected ani-
mals but no cellular infiltrates (data not shown). There
were no readily detectable lesions in the brain or spinal
cord (Fig. 2, d and f). These results suggested that limb pa-
ralysis was a result of damage to peripheral nerves as op-
posed to a CNS or primary muscle disorder.
The nerve damage was confirmed by morphological
analysis of mice with SAPP. As seen in Fig. 3, significant
demyelination was detected in toluidine blue stained one
micrometer cross sections from sciatic nerves (Fig. 3 a).
Most significantly, on tease preparations, some fibers re-
vealed an increase in the number of Nodes of Ranvier with
irregular spacing and irregular thickness of myelin sheets,
consistent with ongoing myelin repair by Schwann cells
(Fig. 3 b). Electrophysiological studies performed on sciatic
nerves revealed abnormalities indicative of a predominantly
demyelinating neuropathy. There was prolongation of dis-
tal latencies, marked slowing of conduction velocity (17.9 
 
 
 
3.2 m/s in B7-2 KO NOD mice [
 
n
 
 
 
 
 
 12] versus 50.5 
 
 
 
3.8 m/s in WT NOD mice [
 
n
 
 
 
 
 
 8]; Student 
 
t
 
 test: 
 
P
 
 
 
 
 
0.00001), and dispersion of compound muscle action po-
tentials (Fig. 3 c). Partial conduction block was also ob-
served in the more severe cases. Indeed, the peak-to-peak
amplitudes of compound muscle action potentials were de-
creased suggesting some axonal damage secondary to the
demyelination. This axonal damage was confirmed by a
needle exam which revealed fibrillations and positive sharp
waves in intrinsic foot muscles, but not in proximal muscles
(data not shown).
Immunohistochemical studies of the dorsal root ganglia
and peripheral nerves demonstrated an intense, predomi-
nantly mononuclear, cellular infiltrate composed of den-
dritic cells and scattered CD4
 
 
 
 T cells and CD8
 
 
 
 T cells
(Fig. 4). The cellular infiltrate was detected throughout the
sciatic and peripheral nerve tissue, extending to terminal
nerve branches within skeletal muscle. The number of leu-
kocytes was greatest in animals displaying the most severe
disease. At no time were any immune cell infiltrates ob-
served in nerve tissue derived from the CNS of B7-2 KO
mice (data not shown). It remains uncertain whether this is
due to a lack of target antigen in these CNS tissues or inac-
cessibility due to the intact blood–brain barrier in these ani-
mals. The histological results were consistent with an au-
toimmune etiology for the peripheral neuropathy; however,
the results could not distinguish between a humoral versus
cellular basis for the disease. Therefore, passive and adoptive
transfer studies were performed. No NOD.SCID animals
receiving sera from SAPP animals developed neuropathy
 
within 20 wk after transfer (data not shown). Next, whole
lymph node and spleen cells from neuropathic B7-2 KO
NOD mice were cultured for 2 d in vitro with anti-CD3
and anti-CD28 mAbs and transferred into the NOD.SCID
recipients. The transfer of 15 
 
 
 
 10
 
6
 
 reactivated T cells from
the SAPP mice induced a severe peripheral neuropathy (but
not diabetes, data not shown) in 100% of NOD.SCID re-
cipients within 7 wk of transfer (Fig. 5 a). By comparison,
injection of reactivated T cells from age-matched nondia-
betic WT NOD animals induced diabetes (data not shown)
but not peripheral neuropathy (Fig. 5 a). These results sug-
gest that SAPP is mediated by antigen-specific T cells. The
individual role of CD4
 
 
 
 T cells versus CD8
 
 
 
 T cells in the
pathogenesis of the disease was examined. The transfer of
purified, reactivated, CD4
 
 
 
 T cells induced the disease in
the NOD.SCID mice whereas CD4
 
 
 
 T-depleted cells did
Figure 3. B7-2 /  neuropathic NOD mice have a demyelinating dis-
ease. (a) Toluidine blue staining on cross section of sciatic nerves showing
destruction of myelin sheets in B7-2 /  neuropathic mice evidenced by
lower sheet density (right panel). (b) Individual nervous fibers released by
tease preparation of sciatic nerves showing clear evidence of demyelina-
tion in B7-2 /  mice (right panels). In addition some fibers have in-
creased number of nodes of Ranvier (arrows) due to myelin sheet regen-
eration by newly dividing Schwann cells (middle panel). (c) Compound
muscle action potentials were obtained upon distal (ankle) and proximal
(thigh) stimulation of sciatic nerve. Examples of nerve conduction studies
showing prolonged latencies, slowed conduction velocity, and dispersion
of compound muscle action potentials in B7-2 /  neuropathic mice
compared with controls (bottom panel). 
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not (Fig. 5 b). In the mice transferred with purified CD4
 
 
 
 T
cells, affected nerves revealed the presence of an abundant
CD4
 
 
 
 T cell population but no CD8
 
 
 
 T cells (data not
shown). Furthermore, SAPP was rapidly induced in
NOD.SCID mice after transfer of CD8
 
 
 
 T cell–depleted
preparations from affected mice (data not shown). These re-
sults highlight the necessary and sufficient role played by
CD4
 
 
 
 T cells in the effector phase of this autoimmune dis-
ease; however, the results do not rule out that pathogenic
CD8
 
 
 
 T cells or Abs may play a role in the disease or medi-
ate it after longer periods of time.
B7-1 has been shown to be a critical costimulatory mol-
ecule in experimental autoimmune encephalomyelitis, an
autoimmune disease of the CNS (6, 15). We thus analyzed
Figure 4. Nerves of B7-2 /  neuropathic NOD mice are highly infiltrated with CD4 , CD8  T cells and dendritic cells. (Left panel) Frozen sections
of sciatic nerve of a 30-wk-old B7-2 /  neuropathic female and an age match control mouse were immunostained for the presence of CD4  and CD8 
T cells and dendritic cells (DC). No infiltrate was detected in B7-2 /  mice (dark oblong structures are nuclei of Schwann cells) whereas B7-2 /  mice
presented abundant infiltration (dark round structures are stained cells). (Right panel) Frozen sections of sciatic nerve of a 28-wk-old B7-2 /  neuropathic
female and an age-matched B7-2 /  B6 male mouse were immunostained for the presence of CD4 (green, top panel) and B7-1 (green, bottom panel).
No infiltrate or B7-1 staining was detected in a B7-2 /  B6 mouse whereas B7-2 /  NOD mice presented abundant infiltration and B7-1 expression.
Figure 5. Essential role of CD4  T cells in the neuropathy of B7-2 / 
NOD mice. (a) Total spleen and lymph node cells from B7-2 /  neuro-
pathic NOD mice or age match NOD controls were stimulated in vitro
with anti-CD3 and anti-CD28 mAbs and injected into five NOD.SCID
mice. Symptoms of neuropathy were then checked weekly. Inset: neuro-
pathic NOD.SCID mouse displaying complete paralysis of hind limbs.
(b) CD4  T cells, CD4-depleted cells, and whole cells, purified from
spleen and lymph nodes of B7-2 /  neuropathic NOD mice, were stim-
ulated in vitro with anti-CD3 and anti-CD28 mAbs and injected into 14,
9, and 16 NOD.SCID mice, respectively. Data are from three indepen-
dent experiments.682 Spontaneous Autoimmune Neuropathy in B7-2–deficient Mice
levels of B7-1 expression in the sciatic nerves (and spleen)
of B7-2 KO mice by flow cytometry (Fig. 6). B7-1 expres-
sion was easily detected in sciatic nerves of neuropathic B7-2
KO mice. This expression was strictly limited to infiltrat-
ing CD45-positive cells and could not be detected in the
absence of a mononuclear infiltrate in 12–14-wk-old B7-2
KO or B7-2 WT mice (Fig. 6). Furthermore, expression of
B7-1 in the nerves of neuropathic animals was high on
CD11b-positive and CD11c-positive cells (Fig. 6, and data
not shown), suggesting that antigen-presenting cells infil-
trating the peripheral nerves expressed high levels of B7-1.
B7-1 expression could be readily detected on some spleno-
cytes of B7-2 KO animals, although this expression was
lower than observed on the infiltrating CD11b-positive
cells of sciatic nerves (data not shown). In contrast B7-1
was not detected in the spleen of WT NOD mice (data not
shown). Finally, we compared CD4 and B7-1 staining by
immunohistochemistry. As noted in Fig. 4 (right panel), in-
cubation with inflamed sciatic nerve revealed B7-1 staining
of the infiltrating cells; however, the staining pattern for
B7-1 and CD4 does not appear to be overlapping. In fact,
two-color analyses suggested a significant overlap of mono-
nuclear infiltrate and B7-1 staining in this tissue (data not
shown). Importantly, there was no B7-1 staining in the B7-2
KO B6 mouse consistent with the correlation of B7-1 ex-
pression and the disease. Finally, it should be emphasized
that there was no infiltrate in the B7-2 KO mice on the B6
background consistent with the absence of any disease in
these animals.
Discussion
Increasing evidence suggests that a variety of generalized
mechanisms (i.e., decreased regulatory mechanisms and cy-
tokine production, altered thymic selection, expression of
specific MHC class II haplotypes, etc.) may play a critical
role in the increased autoimmune disease incidence ob-
served in certain genetic settings (14, 16, 17). Genes of sus-
ceptibility linked to multiple autoimmune diseases have
been identified in both NOD mice and human (14, 17–
20). For instance, the DR3-DQB1*0201 haplotype in
humans has been associated with multiple autoimmune dis-
eases in humans including type 1 diabetes, Addison’s dis-
ease, Graves’ disease, and Hashimoto’s thyroiditis (21).
Moreover a single individual diabetic patient could present
other autoimmune syndromes (17). Similarly, diabetic-
prone NOD mice also exhibit immune reactions against
multiple glands such as thyroid or salivary glands, T cell au-
toreactivity to CNS Ag and some features of nonorgan-
specific autoimmune disease such as late-onset antinuclear
Abs and hemolytic anemia (22–24). Thus, the development
of SAPP in B7-2–deficient NOD mice, not observed in
other mouse strains deficient in B7-2, could be related to
the general susceptibility to autoimmunity of these mice.
SAPP could share a subset of immunological and genetic
attributes to those associated with the endocrine autoim-
munity in this mouse strain.
Importantly, the regulatory role of B7-2 in protection
from cryptic SAPP development was demonstrated in two
independent models: in genetically modified B7-2 KO
mice and in WT animals treated with blocking anti–B7-2
mAb. The lower incidence of neuropathy in the latter
model is likely due to incomplete penetrance of the Ab
into relevant tissues and the limited time of treatment. In
addition, the induction of neuropathy after B7-2 disruption
did not simply result from the prevention of diabetes. In-
deed, more than 150 treatments preventing diabetes have
been reported. None of them has been described to induce
peripheral neuropathy.
Another significant finding in our study was the polar-
ization of the autoimmune response in the B7-2 KO
NOD mice, which develop SAPP but are free from the
development of diabetes, pointing to the importance of
immune dysregulation in the shift from one autoimmune
disease to another. The lack of diabetes in these mice did
not seem to be due to a lack of islet-reactive diabetogenic
T cells. Indeed, in preliminary results we have observed
that splenocytes from B7-2 KO mice could induce diabe-
tes when transferred into NOD.SCID mice (data not
shown). However, this required the depletion from the in-
noculum of the CD4 CD25  T cells, which regulate au-
toimmune diabetes (25).
The development of SAPP in B7-2 KO NOD mice was
unexpected. A recent study showed the presence of my-
elin-reactive T cells in the spleen of WT NOD mice (24).
Such auto-reactive T cells, upon migration in peripheral
nerves, could play a role in SAPP. In addition to T cells,
peripheral nerves of neuropathic B7-2 KO mice were infil-
trated with high number of myeloid cells identified by ex-
pression of CD11c and/or CD11b, most of them being
myeloid type dendritic cells (data not shown). The high
levels of B7-1 expression on these professional antigen-
presenting cells likely amplified the activation of myelin-
Figure 6. Expression of B7-1 in B7-2KO NOD mice. Sciatic nerve
tissues from 28-wk-old neuropathic B7-2 KO or 12–14-wk-old B7-2
KO and B7-2 WT females were digested with collagenase. Indicated cell
subpopulations (CD45  cell population in B7-2 WT and young B7-2
KO mice) were then analyzed for B7-1 expression (shaded histograms) by
flow cytometry. White histograms show the staining with the isotypic
control Ab.683 Salomon et al.
reactive T cells, leading to destruction of myelin sheets and
development of SAPP. Whether B7-1 upregulation played
a role in initiating and sustaining the destructive inflamma-
tory infiltrate or conversely was a result of the local inflam-
matory milieu is currently under investigation. However,
the striking overexpression of B7-1 in B7-2KO mice com-
pared with NOD mice suggests that B7-1 played an active
role in the development of SAPP in B7-2 KO mice. In this
regard, it is interesting to note that B7-1 was selectively
upregulated in nervous tissue of mice with experimental
allergic encephalomyelitis (26). In this murine model,
blockade of B7-1 using Fab fragments of anti–B7-1 mAbs
reduced IFN-  production and prevented disease whereas
blockade with anti–B7-2 exacerbated disease (6, 15). Inter-
estingly, treatment with intact anti–B7-1 mAbs exacer-
bated the pathology for unknown reasons (27). Similarly,
treatment of B7-2 KO NOD mice with this reagent re-
sulted in a rapid and profound induction of diabetes and
neuropathy (data not shown). Thus, future experiments
will focus on the use of Fab fragments of anti–B7-1 mAbs
to avoid potential complications of an “activating” form of
the blocking reagent. Finally, the absence of B7-1 expres-
sion in the nerves before infiltration and the restriction of
B7-1 expression to hematopoietic cells later in the course
of the disease does not rule out a major role for resident
nerve cells such as Schwann cells in the development of the
inflammation in the nerves. However, it is unlikely that
the nerve cells directly stimulate (costimulate) the immune
response to initiate disease in these animals. Rather, the
upregulation of B7-1 in the spleen of B7-2 KO NOD
mice could increase the activation of myelin reactive T
cells, identified in WT NOD mice (24), which then mi-
grated into the peripheral nerves.
The shift from one autoimmune disease to another is
reminiscent of multiple studies in mice and humans that
showed concomitant disappearance of one autoimmune
syndrome and worsening of a second. NOD mice treated
with complete Freund’s adjuvant are protected from diabe-
tes but at the same time they can develop lupus (23). Mul-
tiple sclerosis patients treated with anti-CD52 Ab showed
improvement of their neurologic disease but fully one third
of them developed Graves’ disease (unpublished data).
These results suggest that autoimmune-prone individuals
have immune dysfunctions that can manifest as distinct dis-
ease entities perhaps dependent upon the costimulatory mi-
lieu. For instance, differential expression and ligation of
B7-2 and B7-1 at distinct anatomical sites may lead to dif-
ferent outcomes.
Importantly, SAPP has many similarities to human au-
toimmune demyelinating neuropathies such as chronic in-
flammatory demyelinating polyneuropathy (CIDP) and
Guillain-Barré syndrome, although the slow progressive
course in SAPP suggests that the immune mechanisms are
more similar to those of CIDP (28). This new autoimmune
model could help understand the pathophysiology of some
autoimmune diseases of the nervous system such as CIDP.
The essential role of CD4  T cell in the effector phase of
SAPP could indicate a critical role of these cells in CIDP.
SAPP adds to the very short list of models of spontane-
ous autoimmune disease mouse models including diabetes,
lupus, rheumatoid arthritis, and colitis. In these models,
self-tolerance breakdown probably results from chronic
stimulation of autoreactive lymphocytes. The pathophysi-
ology of these diseases could be fundamentally different to
that observed in experimental autoimmune models in
which self-tolerance breakdown is rapid and results from
strong immunization with a specific autoantigen. In this re-
gard, CD28 ligation blockade reduced severity or pre-
vented various experimental autoimmune diseases whereas
it exacerbated spontaneous autoimmune diabetes (8–10,
25, 29). Similarly, B7-2 ligation blockade promotes SAPP
in NOD mice. Although these findings raise concerns
about the use of costimulatory blockade in the patient set-
ting, they provide a model for analyzing the genetic and
immunological basis for autoimmunity that may lead to
new insights into these complex disorders.
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